Aurobindo Pharma Limited (AUROPHARMA) reports Q1FY27 results with ₹9,150 Cr revenue, 16.3% Y-o-Y growth, and a 25.2% rise in net profit.
Aurobindo Pharma Limited (AUROPHARMA) secures FTC approval to acquire Lannett Company, expanding its U.S. manufacturing capabilities.
Aurobindo Pharma Limited (AUROPHARMA) secures final approval from US FDA for Tofacitinib Tablets, targeting a US$494 million market.
Aurobindo Pharma Limited (AUROPHARMA) inaugurates TheraNym, a pioneering biologics contract manufacturing facility in Hyderabad, India, with MSD as its ancho.
Aurobindo Pharma Limited (AUROPHARMA) announced consolidated financial results for Q4 and FY 2026, showing a 5.6% YoY revenue increase to INR 8,853 Cr.
